Riskpilot← Back to searchSign inGet full accessTRACER PHARMA ApS
APSIn liquidationCVR 34090106Agern Alle 7Research and experimental development on natural sciences and engineering · NACE 7210Est. 20111 employees
Revenue 2025
DKK 5,2M
-4% vs 2024
EBITDA margin
16.4%
-62% vs 2024
Equity ratio
38.2%
Financial strength
Net profit 2025
DKK 688K
-60% vs 2024
| Revenue | DKK 5,2M | -4% |
| EBITDA | DKK 854K | -62% |
| Net profit | DKK 688K | -60% |
| Total assets | DKK 2,3M | -51% |
| Equity | DKK 867K | -58% |
| Employees | 1 | — |
Legal name
TRACER PHARMA ApS
CVR number
34090106
Legal form
Anpartsselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
20. december 2011
Share capital
DKK 80.000
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2025-04-30
Financial year
January – December
Signatory rights
Virksomheden tegnes af en likvidator
Address
Agern Alle 7
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.183 | 2.016 | 2.169 | 3.105 | 2.509 | 3.301 | 3.027 | 4.367 | 3.968 | 3.883 | 4.076 | 5.413 | 5.204 |
| Staff expenses | -2.358 | -2.100 | -2.307 | -2.331 | -2.156 | -2.335 | -2.934 | -3.412 | -2.760 | -3.552 | -3.807 | -2.906 | -4.607 |
| EBITDA | 826 | -83 | -139 | 774 | 353 | 966 | 93 | 955 | 1.208 | 331 | 269 | 2.250 | 854 |
| Depreciation & amort. | -40 | -30 | -193 | -438 | -429 | -418 | -508 | -352 | -119 | -122 | -122 | -67 | -40 |
| EBIT | 786 | -114 | -331 | 336 | -76 | 548 | -415 | 603 | 1.089 | 209 | 147 | 2.183 | 813 |
| Net financials | -7 | 288 | 377 | -175 | 106 | -9 | -5 | -19 | -22 | -23 | -22 | 4 | 94 |
| Profit before tax | 779 | 174 | 46 | 162 | 30 | 539 | -420 | 584 | 1.067 | 186 | 126 | 2.186 | 907 |
| Tax | 208 | 51 | 16 | 39 | 10 | 122 | -89 | 128 | 235 | 41 | 29 | 481 | 220 |
| Net profit | 571 | 123 | 30 | 123 | 20 | 417 | -330 | 455 | 832 | 145 | 97 | 1.705 | 688 |
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 4.230 | 1.557 | 4.910 | 3.388 | 3.527 | 2.990 | 2.863 | 2.528 | 3.250 | 3.439 | 3.025 | 4.662 | 2.272 |
| Equity | 651 | 204 | 114 | 207 | 227 | 525 | 194 | 650 | 1.482 | 1.627 | 1.374 | 2.079 | 867 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 164 | 0 | 0 | 0 | 461 | 0 |
| Short-term debt | 3.577 | 1.348 | 4.774 | 3.122 | 3.249 | 2.414 | 2.668 | 1.714 | 1.734 | 1.809 | 1.651 | 1.865 | 1.404 |
| Total debt | 3.577 | 1.348 | 4.774 | 3.122 | 3.249 | 2.414 | 2.668 | 1.878 | 1.734 | 1.809 | 1.651 | 2.326 | 1.404 |
EBITDA margin
16.4%
This company
15.8%
Market median
+4% vs market
20132025
Equity ratio
38.2%
This company
38.2%
Market median
+0% vs market
20132025
Return on equity
79.3%
This company
18.4%
Market median
+331% vs market
20132025
Net profit margin
13.2%
This company
8.1%
Market median
+63% vs market
20132025
Asset turnover
2.29×
This company
1.12×
Market median
+104% vs market
20132025
Debt / equity
1.62×
This company
0.62×
Market median
-161% vs market
20132025
- Annual report 2025Filed via CVR / Virk · Period 2024-05-01 – 2025-04-30
- Annual report 2024Filed via CVR / Virk · Period 2023-05-01 – 2024-04-30
- Annual report 2023Filed via CVR / Virk · Period 2022-05-01 – 2023-04-30
- Annual report 2022Filed via CVR / Virk · Period 2021-05-01 – 2022-04-30
- Annual report 2021Filed via CVR / Virk · Period 2020-05-01 – 2021-04-30
- Annual report 2020Filed via CVR / Virk · Period 2019-05-01 – 2020-04-30
- Annual report 2019Filed via CVR / Virk · Period 2018-05-01 – 2019-04-30
- Annual report 2018Filed via CVR / Virk · Period 2017-05-01 – 2018-04-30
- Annual report 2017Filed via CVR / Virk · Period 2016-05-01 – 2017-04-30
- Annual report 2016Filed via CVR / Virk · Period 2015-05-01 – 2016-04-30
- Annual report 2015Filed via CVR / Virk · Period 2014-05-01 – 2015-04-30
- Annual report 2014Filed via CVR / Virk · Period 2013-05-01 – 2014-04-30
- Annual report 2013Filed via CVR / Virk · Period 2011-12-20 – 2013-04-30
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
EE Unofficial title | Unofficial title | 2025 | — | — |
JB Chief Executive Officer | Chief Executive Officer | 2013 | — | — |
MH Chief Executive Officer | Chief Executive Officer | 2019 | — | — |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Unacceptable Holding ApS | Company | 100.0% | 100.0% | 2021 |
DK INVEST AF 19.12.2011 ApS | Company | 100.0% | 100.0% | 2011 |
| Individual | 100.0% | 100.0% | 2011 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of TRACER PHARMA ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Enver Edwin Medjedovic Hansen | Unofficial title | 0 companies |
| Jette Bjerrum | Chief Executive Officer | 0 companies |
| Morten Hagelsten Jacobsen | Chief Executive Officer | 0 companies |